Phil Skolnick Biography and Net Worth

Insider of Opiant Pharmaceuticals

Phil Skolnick has more than 45 years of pharmaceutical experience, with leadership positions in academia, government and industry. Prior to Opiant, he served as the Director, Division of Therapeutics and Medical Consequences at the National Institute on Drug Abuse, NIH (2010-2017). He was Chief Scientific Officer (2001-2009) and President (2007-2009) of DOV Pharmaceutical, Inc. He was a Lilly Research Fellow (Neuroscience) at Lilly Research Laboratories (1997-2000). Prior to this, he served as Senior Investigator and Chief, Laboratory of Neuroscience, at the NIH from 1986-1997. He has also served as a Research Professor of Psychiatry at New York University-Langone Medical Center, Research Professor of Psychiatry at the Uniformed Services University of the Health Sciences, Adjunct Professor of Anesthesiology at Johns Hopkins University, and Adjunct Professor of Pharmacology and Toxicology at Indiana University School of Medicine.

Throughout his career, he has been attached to more than 550 publications in the fields of molecular and clinical neuropsychopharmacology. Dr. Skolnick received a BS from Long Island University (summa cum laude) and a PhD from the Department of Pharmacology, George Washington University School of Medicine. He has been awarded a DSc, honoris causa from Long Island University and the University of Wisconsin-Milwaukee.

What is Phil Skolnick's net worth?: The estimated net worth of Phil Skolnick is at least $0.00 as of July 14th, 2022. Dr. Skolnick owns 23,818 shares of Opiant Pharmaceuticals stock worth more than $0 as of April 26th. This net worth approximation does not reflect any other investments that Dr. Skolnick may own. Learn More about Phil Skolnick's net worth.
How do I contact Phil Skolnick?: The corporate mailing address for Dr. Skolnick and other Opiant Pharmaceuticals executives is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. Opiant Pharmaceuticals can also be reached via phone at (310) 598-5410 and via email at [email protected]. Learn More on Phil Skolnick's contact information.
Has Phil Skolnick been buying or selling shares of Opiant Pharmaceuticals?: Phil Skolnick has not been actively trading shares of Opiant Pharmaceuticals in the last ninety days. Most recently, Phil Skolnick sold 627 shares of the business's stock in a transaction on Thursday, July 14th. The shares were sold at an average price of $11.85, for a transaction totalling $7,429.95. Following the completion of the sale, the insider now directly owns 23,818 shares of the company's stock, valued at $282,243.30. Learn More on Phil Skolnick's trading history.
Who are Opiant Pharmaceuticals' active insiders?: Opiant Pharmaceuticals' insider roster includes Craig Collard (Director), Roger Crystal (CEO), David O'Toole (CFO), Matthew Ruth (Insider), Michael Sinclair (Director), Phil Skolnick (Insider), and Thomas Thomas (Director). Learn More on Opiant Pharmaceuticals' active insiders.

Phil Skolnick Insider Trading History at Opiant Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/14/2022	Sell	627	$11.85	$7,429.95	23,818
1/27/2022	Sell	1,518	$26.19	$39,756.42
1/10/2022	Sell	385	$30.49	$11,738.65
12/3/2019	Sell	7,143	$13.47	$96,216.21
11/5/2019	Sell	10,000	$15.80	$158,000.00
10/3/2019	Sell	10,000	$14.68	$146,800.00
9/4/2019	Sell	10,000	$14.15	$141,500.00	10,000
8/2/2019	Sell	10,000	$11.60	$116,000.00
7/2/2019	Sell	10,000	$13.19	$131,900.00
6/4/2019	Sell	10,000	$11.71	$117,100.00
5/2/2019	Sell	10,000	$11.39	$113,900.00
4/2/2019	Sell	10,000	$12.66	$126,600.00
3/1/2019	Sell	10,000	$14.95	$149,500.00
2/4/2019	Sell	10,000	$15.32	$153,200.00
1/4/2019	Sell	10,000	$13.76	$137,600.00
12/6/2018	Sell	4,321	$16.06	$69,395.26
11/5/2018	Sell	1,821	$18.01	$32,796.21
10/4/2018	Sell	4,778	$18.32	$87,532.96

Phil Skolnick Buying and Selling Activity at Opiant Pharmaceuticals

Opiant Pharmaceuticals Company Overview

Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.

Today's Range

Now: N/A

50 Day Range

MA: $20.58

$20.03

$21.10

2 Week Range

Now: N/A

Volume

562,700 shs

Average Volume

77,920 shs

Market Capitalization

$108.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84

The Gold Grab of the Century

From Colonial Metals | Ad

When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.

That's why we have released our Free Precious Metals Investment Guide.